-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Initiates Coverage On Alto Neuroscience with Buy Rating, Announces Price Target of $15

Benzinga·09/29/2025 11:24:50
Listen to the news
Chardan Capital analyst Rudy Li initiates coverage on Alto Neuroscience (NYSE: ANRO) with a Buy rating and announces Price Target of $15.